EMA
- Application: EMEA/H/C/002809
- Local brand name: Incruse Ellipta (previously Incruse)
- Status: approved
UMECLIDINIUM BROMIDE (UMECLIDINIUM BROMIDE) regulatory status in European Union.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. EMA has authorised it.
Marketing authorisation holder not available in our data.